IRADIMED CORPORATION to Hold 2017 Fourth Quarter Financial Results Conference Call on February 6th
January 26 2018 - 7:00AM
IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the
Company will release its 2017 fourth quarter financial results
before the market opens on Tuesday, February 6th.
IRADIMED management will host a conference call the same day
beginning at 11:00 a.m. Eastern Time to discuss those results and
to answer questions.
Individuals interested in listening to the conference call may
do so by dialing 1-844-413-1781 for domestic callers, or
1-716-247-5767 for international callers, and entering reservation
code 5097406.
The conference call will also be available real-time via the
Internet at http://www.iradimed.com/en-us/investors/events/. A
recording of the call will be available on the Company’s website
for 90 days following completion of the call.
About IRADIMED
CORPORATION
IRADIMED CORPORATION is a leader in the development of
innovative magnetic resonance imaging (MRI) compatible medical
devices. We are the only known provider of non-magnetic intravenous
(IV) infusion pump system that is specifically designed to be safe
for use during MRI procedures. We were the first to develop an
infusion delivery system that largely eliminates many of the
dangers and problems present during MRI procedures. Standard
infusion pumps contain magnetic and electronic components which can
create radio frequency interference and are dangerous to operate in
the presence of the powerful magnet that drives an MRI system. Our
patented MRidium® MRI compatible IV infusion pump system has been
designed with a non-magnetic ultrasonic motor, uniquely-designed
non-ferrous parts and other special features in order to safely and
predictably deliver anesthesia and other IV fluids during various
MRI procedures. Our pump solution provides a seamless approach that
enables accurate, safe and dependable fluid delivery before, during
and after an MRI scan, which is important to critically-ill
patients who cannot be removed from their vital medications, and
children and infants who must generally be sedated in order to
remain immobile during an MRI scan.
Our 3880 MRI compatible patient vital signs monitoring system
has been designed with non-magnetic components and other special
features in order to safely and accurately monitor a patient’s
vital signs during various MRI procedures. The IRADIMED 3880
system operates dependably in magnetic fields up to 30,000 gauss,
which means it can operate virtually anywhere in the MRI scanner
room. The IRADIMED 3880 has a compact, lightweight design
allowing it to travel with the patient from their critical care
unit, to the MRI and back, resulting in increased patient safety
through uninterrupted vital signs monitoring and decreasing the
amount of time critically ill patients are away from critical care
units. The features of the IRADIMED 3880 include: wireless ECG
with dynamic gradient filtering; wireless SpO2 using Masimo®
algorithms; non-magnetic respiratory CO2; non-invasive blood
pressure; patient temperature, and; optional advanced multi-gas
anesthetic agent unit featuring continuous Minimum Alveolar
Concentration measurements. The IRADIMED 3880 MRI compatible
patient vital signs monitoring system has an easy-to-use design and
allows for the effective communication of patient vital signs
information to clinicians.
For more information please visit www.iradimed.com.
Media Contact:Chris ScottChief Financial OfficerIRADIMED
CORPORATION(407) 677-8022 InvestorRelations@iradimed.com
iRadimed (NASDAQ:IRMD)
Historical Stock Chart
From Jun 2024 to Jul 2024
iRadimed (NASDAQ:IRMD)
Historical Stock Chart
From Jul 2023 to Jul 2024